Dysthymia and Apathy - Diagnosis and Treatment

25/4/2021 Dysthymia and Apathy: Diagnosis and Treatment
Depress Res Treat. 2011; 2011: 893905. PMCID: PMC3130974

Published online 2011 Jun 27. doi: 10.1155/2011/893905 PMID: 21747995
Dysthymia and Apathy: Diagnosis and Treatment

Junko Ishizaki 1, 2 , and Masaru Mimura 3 ,*
1Department of Psychiatry, Nagata Hospital, 5173 Goji-cho, Miyakonojo-shi, Miyazaki 885-0084, Japan
2Department of Neuropsychiatry, Showa University School of Medicine, 6-11-11 Kita-Karasuyama, Setagaya-
ku, Tokyo 157-8577, Japan

3Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo
160-8582, Japan
*Masaru Mimura: mimura@a7.keio.jp
Academic Editor: Mathias Berger
Received 2010 Dec 6; Accepted 2011 Apr 24.
Copyright © 2011 J. Ishizaki and M. Mimura.
This is an open access article distributed under the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Dysthymia is a depressive mood disorder characterized by chronic and persistent but mild depression.
It is often difficult to be distinguished from major depression, specifically in its partially remitted state
because “loss of interest” or “apathy” tends to prevail both in dysthymia, and remitted depression.
Apathy may also occur in various psychiatric and neurological disorders, including schizophrenia,
stroke, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, and dementias such
as Alzheimer's disease, vascular dementia, and frontotemporal dementia. It is symptomatologically
important that apathy is related to, but different from, major depression from the viewpoint of its
causes and treatment. Antidepressants, especially noradrenergic agents, are useful for depression-
related apathy. However, selective serotonin reuptake inhibitors (SSRIs) may be less effective for
apathy in depressed elderly patients and have even been reported to worsen apathy. Dopaminergic
agonists seem to be effective for apathy. Acetylcholine esterase inhibitors, methylphenidate, atypical
antipsychotics, nicergoline, and cilostazol are another choice. Medication choice should be determined
according to the background and underlying etiology of the targeting disease.
1. Dysthymia
Dysthymia is a depressive mood disorder that is characterized by chronic, persistent but mild
depression, affecting 3–6% of individuals in the community [1, 2] and as many as 36% of outpatients
in mental health settings [3]. Although by definition, the depressed mood of dysthymia is not severe
enough to meet the criteria for major depressive disorder, it is accompanied by significant subjective
distress or impairment of social, occupational, or other important activities as a result of mood
disturbance [4]. Dysthymia manifests as a depressed mood persisting for at least two years (one year
for children or adolescents) that lasts for most of the day, occurs on more days than not, and is
accompanied by at least two of the following symptoms:
1. poor appetite or overeating,
2. insomnia or hypersomnia,
3. low energy or fatigue,

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130974/ 1/12
4. low self-esteem,
5. poor concentration or difficulty making decisions,
6. feelings of hopelessness.
To diagnose dysthymia, major depressive episodes must not have occurred during the first two years of
the illness (one year in children or adolescents), and there should be no history of mania. The
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
[5] states that transient euthymic episodes lasting for up to two months may occur during the course of
dysthymia. In the past, dysthymia has had several other names, including depressive neurosis, neurotic
depression, depressive personality disorder, and persistent anxiety depression.
DSM-IV-TR categorizes dysthymia according to several course specifiers: (1) early onset if symptoms
begin before the age of 21 years, (2) late onset if symptoms begin at age 21 or later, and (3) dysthymia
with atypical features if symptoms include increased appetite or weight gain, hypersomnia, a feeling of
leaden paralysis, and extreme sensitivity to rejection.
It is often difficult to differentiate dysthymia from major depression specifically in patients with partial
remission or partial response to treatment. Major depressive disorder, dysthymia, double depression,
and some apparently transient dysphorias may all be manifestations of the same disease process. These
varieties of depressed mood states, while distinct diagnostic entities, share similar symptoms and
respond to similar pharmacologic and psychotherapeutic approaches. Due to the stigma still associated
with depression, many people with this disorder may be unrecognized and untreated. Although
dysthymia has long been considered to be less severe than major depression, the consequences of this
condition are increasingly recognized as potentially grave, including severe functional impairment,
increased morbidity from physical disease, and even an increased risk of suicide.
The pathophysiology of dysthymia is not fully understood. Approximately 30% of individuals with
dysthymia show a switch to hypomanic episodes at some stage [6]. Most people, especially those with
early onset dysthymia, have a family history of mood disorders, including bipolar disorder. One or both
parents may have suffered from major depression. A family history of this illness makes it more likely
for dysthymia to appear in the teenage years or early 20s. Compared with major depression, patients
with dysthymia tend to have more subjective symptoms and less dramatic psychomotor disturbance or
neurovegetative symptoms including abnormalities of sleep, appetite, and energy levels. A longitudinal
prospective study revealed that 76% of dysthymic children develop major depression, and 13% develop
bipolar disorder over follow-up periods of 3–12 years [7]. In the other study, it should be noted that
around 75% of people with dysthymia meet the criteria for at least one major depressive episode, and
this combination is referred to as double depression [8]. Persons with dysthymia who have major
depressive episodes tend to suffer from depression for long periods and spend less time fully recovered
[9]. In a 10-year follow-up study of persons with dysthymia, 73.9% showed recovery from dysthymic
disorder, with a median time to recovery of 52 months, but the estimated risk of relapse into another
period of chronic depression including dysthymia was 71.4%, most commonly within three years [10].
The validity of making a distinction between depressive personality disorder and dysthymia has been a
matter of debate since depressive personality disorder and dysthymia are both classified among the
lesser severity spectrum of depressive disorders. Depressive personality disorder is characterized by a
gloomy or negative outlook on life, introversion, a tendency toward self-criticism, and pessimistic
cognitive processes, with fewer than mood and neurovegetative symptoms, seen in dysthymia.
Dysthymia or depression may coexist with depressive personality disorder, and persons who have
depressive personality disorder are at greater risk of developing dysthymia than healthy persons after
followup for 3 years [11].
2. Treatment for Dysthymia

The best treatment for dysthymia appears to be a combination of psychotherapy and medication. The
positive clinical response to medications like selective serotonin reuptake inhibitors (SSRIs) [12–19],
serotonin norepinephrine reuptake inhibitors (SNRIs) [20, 21], and tricyclic antidepressants (TCAs)
[14, 15] suggests that serotoninergic and noradrenergic systems involve the mechanism of dysthymia.
A systematic review [22, 23] of antidepressant treatment for dysthymia suggests that SSRIs, TCAs, and
monoamine oxidase inhibitors are all equally effective, but SSRIs may be slightly better tolerated.
Success has also been reported with more noradrenergic agents, such as mirtazapine, nefazodone,
venlafaxine, duloxetine, and bupropion. Second-generation antipsychotics showed beneficial effects
compared to placebo for major depressive disorder or dysthymia, but most second-generation
antipsychotics have shown worse tolerability, mainly due to sedation, weight gain, or laboratory data
abnormalities such as prolactin increase. Some evidence indicated beneficial effects of low-dose
amisulpride for dysthymic people [24].
Psychotherapy and medication are both effective treatment modalities for dysthymia and their use in
combination is common. There are many different types of psychotherapy, including cognitive
behavioral therapy, psychodynamic, and insight-oriented or interpersonal psychotherapy, which are
available to help persons with dysthymia. Cognitive Behavioral Analysis System of Psychotherapy
(CBASP) [25] has been attracting more attention for the treatment of chronic depression. CBASP is a
form of psychotherapy that was specifically developed for patients with chronic depression. Its core
procedure is called “situational analysis” and is a highly structured technique that teaches chronically
depressed patients how to handle problematic interpersonal encounters. It encourages patients to focus
on the consequences of their behavior and to use a social problem-solving algorithm to address
interpersonal difficulties. CBASP is more structured and directive than interpersonal psychotherapy
and differs from cognitive therapy by focusing primarily on interpersonal interactions, including
interactions with therapists. Through this psychotherapy, patients come to recognize how their
cognitive and behavioral patterns produce and perpetuate interpersonal problems and learn how to
remedy maladaptive patterns of interpersonal behavior. The combination of medication and
psychotherapy may be much more effective than either one alone [26].
3. Apathy
Dysthymia is essentially defined by the existence of depressive symptoms at some level. However,
some patients who are treated for dysthymia only present with loss of interest and do not have a
depressed mood. This condition should be regarded as apathy. The term “apathy” is derived from the
Greek “pathos” meaning passion, that is, apathy means “lack of passion”. Marin [27] defined the
apathy syndrome as a syndrome of primary lack of motivation, that is, loss of motivation that is not
attributable to emotional distress, intellectual impairment, or diminished consciousness. Starkstein [28]
described the features of apathy as lack of motivation characterized by diminished goal-oriented
behavior and cognition, and a diminished emotional connection to goal-directed behavior. Levy and
Dubois [29] proposed that apathy could be defined as the quantitative reduction of self-generated
voluntary and purposeful behavior. At present, apathy is treated symptomatically. There is no decision
tree for apathy in DSM-IV-TR, but there is a possibility that apathy will come to be managed
independently from mood disorders if the mechanisms involved or treatment strategy is more fully
established in the future. Marin [27] and Starkstein [30] have suggested diagnostic criteria for this
condition. As the basis of specific diagnostic criteria for apathy, abnormalities in aspects of emotion,
cognition, motor function, and motivation have been suggested. Marin has also developed an apathy
rating scale [31], while diagnostic criteria for apathy have been proposed by Starkstein et al. (Table 1).
Table 1
Diagnostic criteria for apathy.
Lack of motivation relative to the patient's previous level of functioning or the standards of his or her age and
culture,
as indicated either by subjective account or observation by others. Presence, with lack of motivation, of at least
one
symptom belonging to each of the following three domains.
(i) Diminished goal-directed behavior:
(a) lack of effort,
(b) dependency on others to structure activity.
(ii) Diminished goal-directed cognition:
(a) lack of interest in learning new things or in new experiences,
(b) lack of concern about one's personal problems.
(iii) Diminished emotion:
(a) unchanging affect,
(b) lack of emotional responsivity to positive or negative events.
The symptoms cause clinically significant distress or impairment in social, occupational, or other important
areas of
functioning. The symptoms are not due to a diminished level of consciousness or the direct physiological
effects of a
substance (e.g., a drug of abuse, a medication).
Adapted from Starkstein [30].
Apathy has received increasing attention because of its effects on emotion, behavior, and cognitive
function. It seems likely that apathy in persons with depression results from alterations of the emotional
and affective processing, but it may typically occur in the absence of a depressed mood (Figure 1).
Figure 1
Apathy versus depression.
Apathy occurs in persons with a variety of psychiatric and neurological disorders including
schizophrenia [32, 33], stroke [34, 35], traumatic brain injury [36], Parkinson's disease [28, 37, 38],
progressive supranuclear palsy [38], Huntington's disease [39, 40], and dementias such as Alzheimer's
disease [30, 41, 42], vascular dementia [43], frontotemporal dementia [41, 42], and dementia due to
HIV [44]. Marin et al. [45] evaluated five subgroups (healthy elderly adults, patients with left
hemispheric stroke, right hemispheric stroke, Alzheimer's disease, and major depression) by using the
apathy evaluation scale [31] and the Hamilton rating scale for depression [46]. Mean apathy scores
were significantly higher than healthy elderly scores in right hemispheric stroke, Alzheimer's disease,
and major depression. Elevated apathy scores were associated with low depression in Alzheimer's
disease, high depression in major depression, and intermediate scores for depression in right
hemispheric stroke. The prevalence of elevated apathy scores ranged from 73% in Alzheimer's disease,
53% in major depression, 32% in right hemispheric stroke, 22% in left hemispheric stroke, and 7% in
normal subjects. They found that the level of apathy and depression varied among diagnostic groups
although apathy and depression were significantly correlated within each group. Thus, apathy is most
often seen clinically within the setting of depression, dementia, or stroke, and problems related to
apathy tend to be important because of its frequency, increasing prevalence, impact on daily life, poorer
rehabilitation outcomes after stroke, and burden on caregivers.
Levy et al. [42, 47] found that patients with frontotemporal dementia and progressive supranuclear
palsy could be discriminated from patients with Alzheimer's disease by their more severe apathy and
relatively less severe depression. Furthermore, they reported that apathy was not correlated with
depression in a combined patient sample, including those with Alzheimer's disease, frontotemporal
dementia, progressive supranuclear palsy, Parkinson's disease, and Huntington's disease. Apathy, but
not depression, was correlated with lower cognitive function as measured by the mini mental state
examination [48]. These results imply that apathy might be a specific neuropsychiatric syndrome that is
distinct from depression but is associated with both depression and dementia. Symptomatologically, it
is important to understand that apathy can occur concomitantly with depression, but is usually different
from it. Depression is a “disorder of emotion”, while apathy is a “disorder of motivation”. Starkstein et
al. [34] studied the frequency of apathy among stroke patients with major depression, minor
depression, or no depression. A fairly large number (23%) of their patients had significant apathy. The
apathetic patients were older, had a higher frequency of major (but not minor) depression, had more
severe physical and cognitive impairment, and had lesions involving the posterior limb of the internal
capsule. In their study, there was a significantly higher frequency of apathy among the patients with
major depression but not those with minor depression or no depression. These findings indicate that
although major depression and apathy occur independently, apathy remains significantly associated
with major depression (but not with minor depression). This is consistent with the results of previous
studies that have differentiated between major and minor depression, including differences of cognitive
function and cortisol suppression after dexamethasone administration [49, 50], which were seen in
patients with major depression but not minor depression.
Apathy is often seen in patients with lesions of the prefrontal cortex [51, 52] and is also frequent after
focal lesions of specific structures in the basal ganglia such as the caudate nucleus, the internal
pallidum, and the medial dorsal thalamic nuclei [53–56]. Apathy is, therefore, one of the clinical
sequelae of disruption of the prefrontal cortex-basal ganglia axis, which is one of the functional
systems involved in the origin and control of self-generated purposeful behavior. Anatomical
localization of regional dysfunction associated with apathy and depression appears to overlap
considerably. Depression has been reported to be more frequent when focal lesions are anterior and
left-sided [57]. Levy and Dubois [29] proposed that the mechanisms responsible for apathy could be
divided into three subtypes of disrupted processing: “emotional-affective”, “cognitive”, and
“autoactivation” loss of psychic self-activation.
4. Treatment for Apathy (Table 2)
Table 2
Possible medications for apathy.
Category Class Main background disease Representative

drug name
Antidepressants SSRIs* Depression Fluvoxamine,
SNRIs** Paroxetine
NaSSAs*** Sertraline
DNRIs**** Milnacipran
Tetracyclic Mirtazapine
antidepressants Bupropion
Tricyclic Maprotiline
antidepressants Amoxapine
Nortriptyline
Dopamine stimulants Dopamine agonists Parkinson's disease, depression (?) Bromocriptine

Pramipexrole
Ropinirole
Amantadine
MAO-B inhibitor Selegiline
Antipsychotic agents Atypical Negative symptoms (apathy-like Clozapine,

antipsychotic symptoms) of schizophrenia Risperidone,
agents Olanzapine,
Quetiapine,
Ziprasidone
Psychostimulants Dopaminergic Primary apathy or apathy syndrome Methylphenidate

agents Pemoline
Amphetamine
Modafinil
Antidementia agents Cholinesterase Alzheimer's disease Donepezil

inhibitors Galantamine
Rivastigmine
Metrifonate
Tacrine
Pyrrolidone-type Stroke, Alzheimer's disease Nefiracetam
nootropic agent
Cerebral circulation and Ergot alkaloid Stroke Nicergoline

metabolism stimulants
Antiplatelet drugs Phosphodiesterase Cilostazol
Open in a separate window
*Selective serotonin reuptake inhibitors: there have been a few reports that SSRIs are not effective for apathy.
**Serotonin-noradrenaline reuptake inhibitors. ***Noradrenergic and specific serotonergic antidepressants.
****Noradrenaline-dopamine reuptake inhibitors.
Taking into consideration the facts that apathy is related to cognitive function and disruption of the
prefrontal cortex-basal ganglia axis, apathy can be considered to resemble subcortical dementia and to
be treatable using dopaminergic agents in central nervous system. A growing number of reports have
documented the treatment of apathy with a variety of psychoactive agents. Various small studies have
indicated that psychostimulants, dopaminergics, and cholinesterase inhibitors might be of benefit for
this syndrome. However, there is no current consensus about treatment for apathy, and information on
pharmacotherapy for this condition mainly depends upon underlying etiology and background disease.
For example, dopamine agonists appear to be promising for ameliorating apathy in patients with
Parkinson's disease while atypical antipsychotics used in schizophrenia and cholinesterase inhibitors
have been reported to be useful for treating apathy in Alzheimer's disease and other dementias.
Therefore, the treatment of apathy should be selected according to its etiology. Depressed patients with
apathy should be given antidepressants, which may also alleviate other symptoms. However, caution
has been raised about using SSRIs for depressed elderly persons because it may worsen apathy [58].
Since frontal lobe dysfunction is considered to be one of the causes of apathy, patients with primary
apathy may respond to psychostimulants such as methylphenidate or dextroamphetamine. There have
also been reports about improvement of apathy and cognitive function after stroke by treatment with
cilostazol [59]. As nonpharmacological methods, cranial electrotherapy stimulation for apathy after
traumatic brain injury [60], and cognitive stimulation therapy for neuropsychiatric symptoms in
Alzheimer's disease [61] might have some value, but evidence awaits future studies.
Apathy syndrome is associated with many diseases, but whether medications are applicable across this
spectrum of background diseases remains unknown. For example, would cholinesterase inhibitors that
are used in patients with Alzheimer's disease be effective for apathy associated with major depression?
These issues should be examined in future studies.
References
1. Weissman MM, Leaf PJ, Bruce ML, Florio L. The epidemiology of dystmia in five communities:
rates, risks, comorbidity, and treatment. The American Journal of Psychiatry. 1988;145(7):815–819.
[PubMed] [Google Scholar]
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R
psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of
General Psychiatry. 1994;51(1):8–19. [PubMed] [Google Scholar]
3. Markowitz JC, Moran ME, Kocsis JH, Frances AJ. Prevalence and comorbidity of dysthymic
disorder among psychiatric outpatients. Journal of Affective Disorders. 1992;24(2):63–71. [PubMed]
[Google Scholar]
4. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from
work in a prospective epidemiologic survey. Journal of the American Medical Association.
1990;264(19):2524–2528. [PubMed] [Google Scholar]
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text
Revision. 4th edition 2000. [Google Scholar]
6. Brunello N, Akiskal H, Boyer P, et al. Dysthymia: clinical picture, extent of overlap with chronic
fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. Journal of
Affective Disorders. 1999;52(1–3):275–290. [PubMed] [Google Scholar]
7. Kovacs M, Akiskal HS, Gatsonis C, Parrone PL. Subthreshold hypomanic symptoms in progression
from unipolar major depression to bipolar disorder. Archives of General Psychiatry. 1994;51(5):365–
374. [PubMed] [Google Scholar]
8. Keller MB, Klein DN, Hirschfeld RMA, et al. Results of the DSM-IV mood disorders field trial. The
American Journal of Psychiatry. 1995;152(6):843–849. [PubMed] [Google Scholar]
9. Klein DN, Schwartz JE, Rose S, Leader JB. Five-year course and outcome of dysthymic disorder: a
prospective, naturalistic follow-up study. The American Journal of Psychiatry. 2000;157(6):931–939.
10. Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course
of dysthymic disorder and double depression. The American Journal of Psychiatry. 2006;163(5):872–
880. [PubMed] [Google Scholar]
11. Kwon JS, Kim YM, Chang CG, et al. Three-year follow-up of women with the sole diagnosis of
depressive personality disorder: subsequent development of dysthymia and major depression. The
American Journal of Psychiatry. 2000;157(12):1966–1972. [PubMed] [Google Scholar]
12. Devanand DP, Nobler MS, Cheng J, et al. Randomized, double-blind, placebo-controlled trial of
fluoxetine treatment for elderly patients with dysthymic disorder. The American Journal of Geriatric
Psychiatry. 2005;13(1):59–68. [PubMed] [Google Scholar]
13. Vanelle JM, Attar-Levy D, Poirier MF, Bouhassira M, Blin P, Olié JP. Controlled efficacy study of
fluoxetine in dysthymia. The British Journal of Psychiatry. 1997;170:345–350. [PubMed]
[Google Scholar]
14. Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing
sertraline and imipramine for the treatment of dysthymia. Archives of General Psychiatry.
15. Kocsis JH, Zisook S, Davidson J, et al. Double-blind comparison of sertraline, imipramine, and
placebo in the treatment of dysthymia: psychosocial outcomes. The American Journal of Psychiatry.
16. Williams JW, Jr., Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in
primary care: a randomized controlled trial in older adults. Journal of the American Medical
Association. 2000;284(12):1519–1526. [PubMed] [Google Scholar]
17. Barrett JE, Williams JW, Jr., Oxman TE, et al. Treatment of dysthymia and minor depression in
primary care: a ramdomized trial in patients aged 18 to 59 years. Journal of Family Practice.
18. Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a
double-blind, placebo-controlled trial in dysthymic patients without major depression. Journal of
Clinical Psychiatry. 2000;61(11):821–827. [PubMed] [Google Scholar]
19. Haykal RF, Akiskal HS. The long-term outcome of dysthymia in private practice: clinical features,
temperament, and the art of management. Journal of Clinical Psychiatry. 1999;60(8):508–518.
20. Hellerstein DJ, Batchelder ST, Little SA, Fedak MJ, Kreditor D, Rosenthal J. Venlafaxine in the
treatment of dysthymia: an open-label study. Journal of Clinical Psychiatry. 1999;60(12):845–849.
21. Ravindran AV, Charbonneau Y, Zaharia MD, Al-Zaid K, Wiens A, Anisman H. Efficacy and
tolerability of venlafaxine in the treatment of primary dysthymia. Journal of Psychiatry and
Neuroscience. 1998;23(5):288–292. [PMC free article] [PubMed] [Google Scholar]
22. De Lima MS, Moncrieff J. Drugs versus placebo for dysthymia. Cochrane Database of Systematic
Reviews. 2000;(4) [PubMed] [Google Scholar]
23. De Lima MS, Hotopf M. A comparison of active drugs for the treatment of dysthymia. Cochrane
Database of Systematic Reviews. 2003;(3) [PMC free article] [PubMed] [Google Scholar]
24. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics

for major depressive disorder and dysthymia. Cochrane Database of Systematic Reviews. 2010;(12)
25. McCullough JP. Psychotherapy for dysthymia: a naturalistic study of ten patients. Journal of
Nervous and Mental Disease. 1991;179(12):734–740. [PubMed] [Google Scholar]
26. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive
behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic
depression. The New England Journal of Medicine. 2000;342(20):1462–1470. [PubMed]
[Google Scholar]
27. Marin RS. Apathy: a neuropsychiatric syndrome. Journal of Neuropsychiatry and Clinical
Neurosciences. 1991;3(3):243–254. [PubMed] [Google Scholar]
28. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability,
validity, and clinical correlates of apathy in Parkinson’s disease. Journal of Neuropsychiatry and
Clinical Neurosciences. 1992;4(2):134–139. [PubMed] [Google Scholar]
29. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia
circuits. Cerebral Cortex. 2006;16(7):916–928. [PubMed] [Google Scholar]
30. Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer’s
disease. The American Journal of Psychiatry. 2001;158(6):872–877. [PubMed] [Google Scholar]
31. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the apathy evaluation scale.
Psychiatry Research. 1991;38(2):143–162. [PubMed] [Google Scholar]
32. Tattan TM, Creed FH. Negative symptoms of schizophrenia and compliance with medication.
Schizophrenia Bulletin. 2001;27(1):149–155. [PubMed] [Google Scholar]
33. Roth RM, Flashman LA, Saykin AJ, McAllister TW, Vidaver R. Apathy in schizophrenia: reduced
frontal lobe volume and neuropsychological deficits. The American Journal of Psychiatry.
34. Starkstein SE, Fedoroff JP, Price TR, Leiguarda R, Robinson RG. Apathy following
cerebrovascular lesions. Stroke. 1993;24(11):1625–1630. [PubMed] [Google Scholar]
35. Withall A, Brodaty H, Altendorf A, Sachdev PS. A longitudinal study examining the independence
of apathy and depression after stroke: the Sydney Stroke Study. International Psychogeriatrics.
36. Marin R, Chakravorty S. Disorders of diminished motivation. In: Silver JM, McAllister TW,
Yudofsky SC, editors. Textbook of Traumatic Brain Injury. Arlington, Va, USA: American Psychiatric;
2005. pp. 337–352. [Google Scholar]
37. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with
Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry. 1999;67(4):492–496.
[PMC free article] [PubMed] [Google Scholar]
38. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive
supranuclear palsy and Parkinson’s disease. Journal of Neuropsychiatry and Clinical Neurosciences.
39. Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional
decline in Huntington’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 2003;74(1):120–
122. [PMC free article] [PubMed] [Google Scholar]
40. Thompson JC, Snowden JS, Craufurd D, Neary D. Behavior in Huntington’s disease: dissociating
cognition-based and mood-based changes. Journal of Neuropsychiatry and Clinical Neurosciences.
41. Chow TW, Binns MA, Cummings JL, et al. Apathy symptom profile and behavioral associations in
frontotemporal dementia vs dementia of Alzheimer type. Archives of Neurology. 2009;66(7):888–893.
[PMC free article] [PubMed] [Google Scholar]
42. Levy ML, Miller BL, Cummings JL, Fairbanks LA, Craig A. Alzheimer disease and frontotemporal
dementias: behavioral distinctions. Archives of Neurology. 1996;53(7):687–690. [PubMed]
[Google Scholar]
43. Staekenborg SS, Su T, van Straaten EC, et al. Behavioural and psychological symptoms in vascular
dementia; differences between small- and large-vessel disease. Journal of Neurology, Neurosurgery
and Psychiatry. 2010;81(5):547–551. [PubMed] [Google Scholar]
44. Rabkin JG, Ferrando SJ, van Gorp W, Rieppi R, McElhiney M, Sewell M. Relationships among
apathy, depression, and cognitive impairment in HIV/AIDS. Journal of Neuropsychiatry and Clinical
Neurosciences. 2000;12(4):451–457. [PubMed] [Google Scholar]
45. Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy
and depression. Journal of Nervous and Mental Disease. 1994;182(4):235–239. [PubMed]
[Google Scholar]
46. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry.
1960;23:56–62. [PMC free article] [PubMed] [Google Scholar]
47. Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive
supranuclear palsy. Neurology. 1996;47(5):1184–1189. [PubMed] [Google Scholar]
48. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the
cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189–198.
49. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Dexamethasone suppression test and
mood following stroke. The American Journal of Psychiatry. 1985;142(3):318–323. [PubMed]
[Google Scholar]
50. Bolla-Wilson K, Robinson RG, Starkstein SE, Boston J, Price TR. Lateralization of dementia of
depression in stroke patients. The American Journal of Psychiatry. 1989;146(5):627–634. [PubMed]
[Google Scholar]
51. Eslinger PJ, Damasio AR. Severe disturbance of higher cognition after bilateral frontal lobe
ablation: patient EVR. Neurology. 1985;35(12):1731–1741. [PubMed] [Google Scholar]
52. Stuss DT, Van Reekum R, Murphy KJ. Differentiation of states and causes of apathy. In: Borod JC,
editor. Neuropsychology of Emotion. Oxford, UK: Oxford University Press; 2000. pp. 340–363.
[Google Scholar]
53. Mendez MF, Adams NL, Lewandowski KS. Neurobehavioral changes associated with caudate
lesions. Neurology. 1989;39(3):349–354. [PubMed] [Google Scholar]
54. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal
ganglia in man. Brain. 1994;117(4):859–876. [PubMed] [Google Scholar]
55. Engelborghs S, Marien P, Pickut BA, Verstraeten S, De Deyn PP. Loss of psychic self-activation
after paramedian bithalamic infarction. Stroke. 2000;31(7):1762–1765. [PubMed] [Google Scholar]
56. Ghika-Schmid F, Bogousslavsky J. The acute behavioral syndrome of anterior thalamic infarction:
a prospective study of 12 cases. Annals of Neurology. 2000;48(2):220–227. [PubMed]
[Google Scholar]
57. Starkstein SE, Robinson RG. Depression in cerebrovascular disease. In: Starkstein SE, Robinson
RG, editors. Depression in Neurologic Disease. Baltimore, Md, USA: Johns Hopkins University Press;
1993. pp. 28–49. [Google Scholar]
58. Wongpakaran N, Van Reekum R, Wongpakaran T, Clarke D. Selective serotonin reuptake inhibitor
use associates with apathy among depressed elderly: a case-control study. Annals of General
Psychiatry. 2006;5(supplement 1):p. S83. [PMC free article] [PubMed] [Google Scholar]
59. Toyoda G, Saika R, Aoyama A, et al. The effect of cilostazol on apathy after cerebral infarction.
Japanese Journal of Stroke. 2011;33:182–184. [Google Scholar]
60. Lane-Brown A, Tate R. Interventions for apathy after traumatic brain injury. Cochrane Database of
Systematic Reviews. 2009;(2) [PMC free article] [PubMed] [Google Scholar]
61. Niu YX, Tan JP, Guan JQ, Wang LN. Cognitive stimulation therapy in the treatment of
neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial. Clinical
Rehabilitation. 2010;12:1102–1111. [PubMed] [Google Scholar]
Articles from Depression Research and Treatment are provided here courtesy of Hindawi Limited

Dysthymia and Apathy - Diagnosis and Treatment

Uploaded by

Document Informationclick to expand document information

Document Informationclick to expand document information

Copyright:

Available Formats

Dysthymia and Apathy - Diagnosis and Treatment

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Dysthymia and Apathy - Diagnosis and Treatment

Uploaded by

Copyright:

Available Formats

25/4/2021 Dysthymia and Apathy: Diagnosis and Treatment

Depress Res Treat. 2011; 2011: 893905. PMCID: PMC3130974

Dysthymia and Apathy: Diagnosis and Treatment

ku, Tokyo 157-8577, Japan

Received 2010 Dec 6; Accepted 2011 Apr 24.

Copyright © 2011 J. Ishizaki and M. Mimura.

1. poor appetite or overeating,

3. low energy or fatigue,

5. poor concentration or difficulty making decisions,

2. Treatment for Dysthymia

Adapted from Starkstein [30].

Apathy versus depression.

4. Treatment for Apathy (Table 2)

Category Class Main background disease Representative

Dopamine stimulants Dopamine agonists Parkinson's disease, depression (?) Bromocriptine

Antipsychotic agents Atypical Negative symptoms (apathy-like Clozapine,

Psychostimulants Dopaminergic Primary apathy or apathy syndrome Methylphenidate

Antidementia agents Cholinesterase Alzheimer's disease Donepezil

Cerebral circulation and Ergot alkaloid Stroke Nicergoline

Open in a separate window

24. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics

You might also like